The Role of Epigenetic Factors in Cancer Drug Resistance

Liye Luan

doi:10.62051/ijphmr.v5n1.01

Authors

Liye Luan

DOI:

https://doi.org/10.62051/ijphmr.v5n1.01

Keywords:

Epigenetics, Cancer, Drug Resistance

Abstract

Cancer is one of the major global health threats. In cancer treatment, the development of drug resistance and tumor recurrence are important clinical challenges. Epigenetic regulation is closely associated with the occurrence and progression of cancer, and many recent studies have also shown that abnormal epigenetic regulation is widely linked to cancer drug resistance. This article reviews the impact of various abnormal epigenetic modifications on cancer drug resistance and discusses the potential of combining epigenetic drugs with existing cancer treatment methods to overcome cancer drug resistance.

References

[1] JACOBSON LO, SPURR CL, et al. Studies on the effect of methyl bis (beta-chloroethyl) amine hydrochloride on diseases of the hemopoietic system [J]. J Clin Invest, 1946, 25(6): 909.

[2] Feinberg AP. The Key Role of Epigenetics in Human Disease Prevention and Mitigation [J]. N Engl J Med, 2018, 378(14): 1323-1334.

[3] Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control [J]. Nat Rev Genet, 2016, 17(8): 487-500.

[4] Song J, Yang P, Chen C, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance [J]. Signal Transduct Target Ther, 2025, 10(1): 219.

[5] Mattei AL, Bailly N, Meissner A. DNA methylation: a historical perspective [J]. Trends Genet, 2022, 38(7): 676-707.

[6] Guo L, Lee YT, Zhou Y, et al. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance [J]. Semin Cancer Biol, 2022, 83: 487-502.

[7] Millán-Zambrano G, Burton A, Bannister AJ, et al. Histone post-translational modifications - cause and consequence of genome function [J]. Nat Rev Genet, 2022, 23(9): 563-580.

[8] He S, Wu Z, Tian Y, et al. Structure of nucleosome-bound human BAF complex [J]. Science, 2020, 367(6480): 875-881.

[9] Nemeth K, Bayraktar R, Ferracin M, et al. Non-coding RNAs in disease: from mechanisms to therapeutics [J]. Nat Rev Genet, 2024, 25(3): 211-232.

[10] Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter [J]. Cancer Res, 2000, 60(21): 6039-44.

[11] Fulda S, Küfer MU, Meyer E, et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer [J]. Oncogene, 2001, 20(41): 5865-77.

[12] Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment [J]. Clin Cancer Res, 2000, 6(12): 4618-27.

[13] Martínez C, García-Martín E, Pizarro RM, et al. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy [J]. Br J Cancer, 2002, 87(6): 681-6.

[14] Wang XQ, Ongkeko WM, Chen L, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway [J]. Hepatology, 2010, 52(2): 528-39.

[15] Kastl L, Brown I, Schofield AC. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells [J]. Int J Oncol, 2010, 36(5): 1235-41.